Clinical Trial Update: Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019) [Phase 2]

View source ↗

Summary

Phase 2 long-term study of navarixin (MK-7123) in moderate to severe COPD was terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Navarixin (SCH 527123, MK-7123) (navarixin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: COPD | Phase 2 | Status: TERMINATED | Results posted: 2014-11-17